Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Hematologic Cancers

The Hematology Clinic is located on the second floor of The Vanderbilt Clinic and is open from Monday through Friday from 8:00 a.m. to 5:00 p.m. Our physicians see patients with hematologic malignancies, benign hematologic disorders and specialty clinics for sickle cell anemia and hemostasis and thrombosis.

Clinical Trials for Hematologic Cancers

40 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Leukemia

VICCHEM1305

04/02/2013

Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Basic Science

Lymphoma
Pediatric Lymphoma

COGAHOD04B1

10/05/2011

AHOD04B1 - Hodgkin Disease (HD) Banking Study

Basic Science

Hematologic

VICCBMT1063

07/27/2011

T-Regulatory Homing Subsets as a Predictor of Response in GVHD Treated with Extracorporeal Photopheresis

Basic Science

Leukemia

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

Hematologic

NMDPBMT0346

07/09/2003

Repository for National Donor Program (NMDP) Research Blood Samples.

Other

Hematologic

VICCBMT1380

02/05/2014

Chronic GVHD Response Measures Validation

Other

Leukemia

VICCPED0995

02/18/2010

Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants

Other

Hematologic

VICCBMT1110

11/02/2001

Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

Supportive Care

Leukemia
Lymphoma

VICCBMT1335

02/18/2014

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP01113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Supportive Care

Hematologic
Leukemia
Multiple Myeloma

VICCBMT12104

02/04/2014

Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)

Supportive Care

Leukemia

PRECOGHEM0901

12/04/2012

Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Supportive Care

Leukemia
Myelodysplastic Syndrome

VICCBMT1218

09/04/2012

A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors

Supportive Care

Leukemia
Pediatric Leukemia

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Treatment

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment

Lymphoma

ECOGHEME1412

07/17/2014

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Treatment

Leukemia

VICCHEM1371

07/14/2014

A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination with Subcutaneous Low-Dose Cytarabine vs. Placebo + Low-Dose Cytarabine in Patients ≥ 65 Years with Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible For Intensive Remission Induction Therapy

Treatment

Leukemia

VICCHEM13110

04/11/2014

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Treatment

Lymphoma

VICCHEM13106

04/09/2014

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT

Treatment

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Treatment

Hematologic

VICCHEM1274

03/31/2014

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Treatment

Hematologic

VICCPED1354

03/17/2014

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

Treatment

Multiple Myeloma

VICCHEM1377

03/14/2014

A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Treatment

Leukemia
Lymphoma
Multiple Myeloma

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Treatment

Hematologic
Leukemia

VICCHEM1346

01/21/2014

A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Treatment

Lymphoma

VICCHEM12103

12/31/2013

Multi-center Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop

Treatment

Leukemia

VICCHEM1336

12/09/2013

A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Treatment

Leukemia

VICCHEM1323

10/03/2013

A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib

Treatment

Leukemia

ECOGHEMS1203

07/26/2013

A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Treatment

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Treatment

Lymphoma

VICCHEM1284

06/05/2013

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Treatment

Multiple Myeloma

VICCHEM12107

03/31/2013

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Treatment

Leukemia

VICCHEM1294

02/25/2013

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Treatment

Leukemia

VICCHEM1289

01/04/2013

Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Leukemia
Pediatric Leukemia

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum

Treatment

Leukemia

ECOGHEME2906

01/20/2012

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)

Treatment

Leukemia

VICCHEM1096

10/24/2011

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Treatment

Hematologic

VICCBMT1158

10/20/2011

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications

Treatment

Lymphoma

VICCDERM1059

06/01/2011

Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma

Treatment

Lymphoma

ECOGHEME2408

05/10/2011

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma